Cargando…
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights
The systemic therapy landscape for hepatocellular carcinoma is rapidly evolving, as the recent approvals of checkpoint inhibitor-based regimens such as atezolizumab–bevacizumab and durvalumab–tremelimumab in advanced disease have led to an expanding therapeutic armamentarium. The development of biom...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362916/ https://www.ncbi.nlm.nih.gov/pubmed/37483311 http://dx.doi.org/10.2147/JHC.S341195 |